Impact of Anti-hyperglycemic Medications on Bone Health

Naim M. Maalouf

doi:10.1007/s12018-015-9176-y

Impact of Anti-hyperglycemic Medications on Bone Health

Naim M. Maalouf

Research output: Contribution to journal › Review article › peer-review

2 Scopus citations

Abstract

Diabetes has recently emerged as an independent risk factor for osteoporosis and osteoporotic fractures, and the underlying mechanisms are starting to be unveiled. Medications used in the treatment of diabetes may impact skeletal health in part through glycemic control. In addition, specific classes of anti-hyperglycemic medications directly influence bone metabolism. In particular, thiazolidinedione use is clearly associated with greater fracture risk. Preliminary studies suggest that medications that enhance the incretin effect (GLP-1 receptor analogs and DPP-4 inhibitors) could have a bone-protective effect, whereas SGLT-2 inhibitors could increase fracture risk. This manuscript reviews the impact of anti-hyperglycemic medications on bone health.

Original language	English (US)
Pages (from-to)	43-52
Number of pages	10
Journal	Clinical Reviews in Bone and Mineral Metabolism
Volume	13
Issue number	1
DOIs	https://doi.org/10.1007/s12018-015-9176-y
State	Published - Feb 27 2015

Keywords

Anti-hyperglycemic
Diabetes
Fracture
Medications
Osteoporosis

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism
Orthopedics and Sports Medicine
Endocrinology

Access to Document

10.1007/s12018-015-9176-y

Cite this

@article{c6db27bb78a542cd91faeb8c8e3cd6b2,

title = "Impact of Anti-hyperglycemic Medications on Bone Health",

abstract = "Diabetes has recently emerged as an independent risk factor for osteoporosis and osteoporotic fractures, and the underlying mechanisms are starting to be unveiled. Medications used in the treatment of diabetes may impact skeletal health in part through glycemic control. In addition, specific classes of anti-hyperglycemic medications directly influence bone metabolism. In particular, thiazolidinedione use is clearly associated with greater fracture risk. Preliminary studies suggest that medications that enhance the incretin effect (GLP-1 receptor analogs and DPP-4 inhibitors) could have a bone-protective effect, whereas SGLT-2 inhibitors could increase fracture risk. This manuscript reviews the impact of anti-hyperglycemic medications on bone health.",

keywords = "Anti-hyperglycemic, Diabetes, Fracture, Medications, Osteoporosis",

author = "Maalouf, {Naim M.}",

note = "Publisher Copyright: {\textcopyright} 2015, Springer Science+Business Media New York.",

year = "2015",

month = feb,

day = "27",

doi = "10.1007/s12018-015-9176-y",

language = "English (US)",

volume = "13",

pages = "43--52",

journal = "Clinical Reviews in Bone and Mineral Metabolism",

issn = "1534-8644",

publisher = "Humana Press",

number = "1",

}

TY - JOUR

T1 - Impact of Anti-hyperglycemic Medications on Bone Health

AU - Maalouf, Naim M.

PY - 2015/2/27

Y1 - 2015/2/27

N2 - Diabetes has recently emerged as an independent risk factor for osteoporosis and osteoporotic fractures, and the underlying mechanisms are starting to be unveiled. Medications used in the treatment of diabetes may impact skeletal health in part through glycemic control. In addition, specific classes of anti-hyperglycemic medications directly influence bone metabolism. In particular, thiazolidinedione use is clearly associated with greater fracture risk. Preliminary studies suggest that medications that enhance the incretin effect (GLP-1 receptor analogs and DPP-4 inhibitors) could have a bone-protective effect, whereas SGLT-2 inhibitors could increase fracture risk. This manuscript reviews the impact of anti-hyperglycemic medications on bone health.

AB - Diabetes has recently emerged as an independent risk factor for osteoporosis and osteoporotic fractures, and the underlying mechanisms are starting to be unveiled. Medications used in the treatment of diabetes may impact skeletal health in part through glycemic control. In addition, specific classes of anti-hyperglycemic medications directly influence bone metabolism. In particular, thiazolidinedione use is clearly associated with greater fracture risk. Preliminary studies suggest that medications that enhance the incretin effect (GLP-1 receptor analogs and DPP-4 inhibitors) could have a bone-protective effect, whereas SGLT-2 inhibitors could increase fracture risk. This manuscript reviews the impact of anti-hyperglycemic medications on bone health.

KW - Anti-hyperglycemic

KW - Diabetes

KW - Fracture

KW - Medications

KW - Osteoporosis

UR - http://www.scopus.com/inward/record.url?scp=84925533456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925533456&partnerID=8YFLogxK

U2 - 10.1007/s12018-015-9176-y

DO - 10.1007/s12018-015-9176-y

M3 - Review article

AN - SCOPUS:84925533456

SN - 1534-8644

VL - 13

SP - 43

EP - 52

JO - Clinical Reviews in Bone and Mineral Metabolism

JF - Clinical Reviews in Bone and Mineral Metabolism

IS - 1

ER -

Impact of Anti-hyperglycemic Medications on Bone Health

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this